Loading...

APC anti-human CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
29E.2A3 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
29E.2A3_APC_CD274_Antibody_FC_091013
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (B7-H1, PD-L1) (clone 29E.2A3) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).
  • 29E.2A3_APC_CD274_Antibody_FC_091013
    PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (B7-H1, PD-L1) (clone 29E.2A3) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).
See APC spectral data
Cat # Size Price Quantity Check Availability Save
329707 25 tests 111€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329708 100 tests 234€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). 

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References

(PubMed link indicates BioLegend citation)
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed
  2. Zhao L, et al. 2018. Oncol Lett. 16:1180. PubMed
  3. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  4. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  5. Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed
  6. Kuryk L, et al. 2019. Oncoimmunology. 8:e1532763. PubMed
  7. Ofori S, et al. 2019. ACS Omega. 4:12584. PubMed
  8. Jin MH, et al. 2019. Cancer Res Treat. N/A. PubMed
  9. Gorris MAJ, et al. 2018. J Immunol. 200:347. PubMed
  10. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  11. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  12. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  13. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  14. Palakurthi S, et al. 2019. Cancer Immunol Res. 1.303472222. PubMed
  15. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
  16. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  17. Jiang L, et al. 2019. Sci Rep. 9:3705. PubMed
  18. Hassounah NB, et al. 2019. Cancer Immunol Immunother. 68:407. PubMed
  19. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  20. Sun X, et al. 2020. Am J Cancer Res. 10:564. PubMed
  21. Leite NC, et al. 2020. Cell Reports. 32(2):107894.. PubMed
  22. Yang WH, et al. 2018. Cancer Res. 78:3761. PubMed
  23. Lim KH, et al. 2020. Nat Commun. 2.889583333. PubMed
  24. Koopmans I, et al. 2018. Oncoimmunology. 7:e1466016. PubMed
  25. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  26. Rauch DA, et al. 2019. Blood. 134:1406. PubMed
  27. Jiang X, et al. 2013. Clin Cancer Res. 19:598. PubMed
  28. Atefi M, et al. 2014. Clin Cancer Res. 20:3446. PubMed
  29. Miranda A, et al. 2015. Cancer Res . 75: 3032-3042. PubMed
  30. Boyerinas B, et al. 2015. Cancer Immunol Res. 3: 1148 - 1157. PubMed
  31. Johnson D, et al. 2016. Nat Commun. 7:10582. PubMed
  32. An L, et al. 2016. Sci Rep. 6: 33346. PubMed
  33. Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed
  34. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  35. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  36. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  37. Huang BR, et al. 2020. Int J Mol Sci. 21:00. PubMed
  38. Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed
  39. Parent AV, et al. 2021. Cell Reports. 36(7):109538. PubMed
  40. Toews K, et al. 2020. Mol Carcinog. 724:59. PubMed
  41. Sapski S, et al. 2020. Cancer Immunol Immunother. 2291:69. PubMed
  42. Chou CW, et al. 2020. Am J Cancer Res. 2621:10. PubMed
  43. Wertel I, et al. 2020. J Immunol Res. 1715064:2020. PubMed
  44. Shevyrev D, et al. 2021. Exp Ther Med. 209:21. PubMed
  45. Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed
  46. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  47. Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed
  48. Hakroush S, et al. 2021. Front Immunol. 11:624547. PubMed
  49. O'Connor MH, et al. 2021. Commun Biol. 4:563. PubMed
  50. Chen LM, et al. 2021. Biosci Rep. Online ahead of print. PubMed
  51. Chen LM, et al. 2021. Biosci Rep. 41:. PubMed
  52. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  53. Kotetsu Y, et al. 2021. Biomedicines. 9:. PubMed
  54. Tanaka C, et al. 2021. Molecules. 26:. PubMed
  55. Tameishi M, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  56. Fu H, et al. 2021. Front Cell Dev Biol. 9:764109. PubMed
  57. Izmirly AM, et al. 2022. PLoS Pathog. 18:e1009903. PubMed
  58. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  59. Baleeiro RB, et al. 2022. Oncoimmunology. 11:2080329. PubMed
  60. Lin G, et al. 2021. Mol Med Rep. 23:. PubMed
  61. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
  62. Li C, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Xi X, et al. 2021. Oncol Lett. 22:716. PubMed
  64. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  65. Wang X, et al. 2022. J Exp Clin Cancer Res. 41:210. PubMed
  66. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  67. Zheng Y, et al. 2022. Transl Res. :. PubMed
  68. Yoshida R, et al. 2022. Cancer Res. :. PubMed
  69. Arlt A, et al. 2020. Mol Oncol. 14:571. PubMed
  70. Cen B, et al. 2021. Oncogene. 40:5984. PubMed
  71. Bernareggi D, et al. 2022. Nat Commun. 13:1899. PubMed
  72. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  73. Thiramanas R, et al. 2020. Cells. 9: . PubMed
  74. Miliotis C, et al. 2021. Cancer Lett. 518:115. PubMed
  75. Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed
  76. Kwee BJ, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  77. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  78. Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed
  79. Liu C, et al. 2022. Cancer Commun (Lond). 42:828. PubMed
  80. Wang Q, et al. 2022. Sci Adv. 8:eabq4722. PubMed
  81. Guo Y, et al. 2023. Mol Carcinog. 62:185. PubMed
  82. De León Rodríguez SG, et al. 2022. J Oncol. 2022:9775736. PubMed
  83. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  84. Wang M, et al. 2022. J Cell Biol. 221:. PubMed
  85. Pan R, et al. 2022. Cell. 185:1521. PubMed
  86. Wang J, et al. 2023. ACS Sens. 8:1200. PubMed
  87. Pinto C, et al. 2023. iScience. 26:106381. PubMed
  88. Lin Z, et al. 2023. J Transl Med. 21:249. PubMed
RRID
AB_940358 (BioLegend Cat. No. 329707)
AB_940360 (BioLegend Cat. No. 329708)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
Go To Top Version: 7    Revision Date: 11.30.2016

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account